1,216 results on '"Lina An"'
Search Results
2. Current myeloproliferative neoplasm scoring systems for clinical practice
3. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
4. Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL
5. A JAK2 mutant to WT prothrombotic cross talk
6. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
7. Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder
8. AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding
9. Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis
10. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
11. Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia
12. Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
13. The early activation of memory B cells from Wiskott-Aldrich syndrome patients is suppressed by CD19 downregulation
14. Abnormalities of follicular helper T-cell number and function in Wiskott-Aldrich syndrome
15. RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group
16. Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells
17. Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup
18. Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
19. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations
20. Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
21. JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms
22. RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group
23. Genetic and Pharmacological Inhibition of BTK Increases Dasatinib Sensitivity in Vitro and In Vivo Including CNS-Infiltrating E2A-PBX1+/Pre-BCR+ ALL Cells
24. Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
25. Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells
26. High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia
27. Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification
28. Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
29. Early Results of MT-401 (Zedenoleucel) in Post-Transplant MRD+ aml Patients
30. Single Tube Molecular Profiling of ALL Samples Reveals Integrated Molecular Signature and Highlights Gene Regulatory Networks
31. Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup
32. Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
33. RAS Pathway Alterations in Pediatric AML Patients
34. Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice
35. The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells
36. Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca2+-dependent tyrosine kinase Pyk2
37. Outcomes after First Rescue Treatment in Patients with Relapsed or Refractory Multiple Myeloma in Colombia
38. High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia
39. Single Tube Molecular Profiling of ALL Samples Reveals Integrated Molecular Signature and Highlights Gene Regulatory Networks
40. Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification
41. Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
42. JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms
43. Early Results of MT-401 (Zedenoleucel) in Post-Transplant MRD+ aml Patients
44. Genetic and Pharmacological Inhibition of BTK Increases Dasatinib Sensitivity in Vitro and In Vivo Including CNS-Infiltrating E2A-PBX1+/Pre-BCR+ ALL Cells
45. RAS Pathway Alterations in Pediatric AML Patients
46. Connexin-43 in the osteogenic BM niche regulates its cellular composition and the bidirectional traffic of hematopoietic stem cells and progenitors
47. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
48. Role and regulation of phosphatidylinositol 3-kinase β in platelet integrin α2β1 signaling
49. AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding
50. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.